Drs. Armstrong, Wallis on AI Biomarkers and HRQoL for Localized Prostate Cancer, mCRPC

Mark Markowski on AI Biomarkers in Prostate Cancer | ASCO 2024Подробнее

AI biomarker predicts benefit of long-term ADT in prostate cancerПодробнее

HRQoL and pain outcomes in mCRPC: abi + ala vs abi + pbo in PROpelПодробнее

How AI is Transforming Prostate Cancer Conversations With Your DoctorПодробнее

Drs. Calais, Wallis on PSMA PET Guided Salvage Radiotherapy for Prostate Cancer Post-ProstatectomyПодробнее

AI-derived pathology-based biomarker predicts benefit of LTADT with RT in localised high-risk PCПодробнее

Dr. Armstrong on the Utility of AR-V7 as a Biomarker in Prostate CancerПодробнее

An AI biomarker to aid in the decision of treatment with ADT for localized prostate cancerПодробнее

An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validat...Подробнее

The history of biomarkers in the treatment of prostate cancerПодробнее

PROpel: analysis of drug interactions between olaparib + abiraterone as 1L therapy in mCRPCПодробнее

Advances in digital pathology and artificial intelligence for prostate cancerПодробнее

Andrew Armstrong, MD, on determining treatment of prostate cancer with DNA repair markersПодробнее

AI and Prostate Cancer This Year - Dr. Timothy Showalter | #activesurveillance #ASPI2020Подробнее

AI Unlocks Prostate Cancer Treatment BenefitsПодробнее

Dr. Armstrong on AR-V7 as a Biomarker of Response to Taxane Chemotherapy in mCRPCПодробнее

Elucidating HRRm status in patients with mCRPC in the PROpel trialПодробнее

New ways for patients to think about advanced stage prostate cancerПодробнее

Episode 93 Highlights - The Artificial Intelligence Revolution in Prostate Cancer DiagnosticsПодробнее